Area of research
Rheumatology · Pathology and Forensic Medicine
Research interest
Research interests include Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Spine and Intervertebral Disc Pathology, and Autoimmune and Inflammatory Disorders Research.
MRI structural lesions in axSpA: distinguishing outcome measures from diagnostic thresholds.
Use of clustering techniques for clinical and epidemiological research: practical tips using an example from rheumatology.
Cost optimizing tocilizumab therapy in stable rheumatoid arthritis: a dose de-escalation nomogram to prevent overuse and unnecessary costs.
Coping with rheumatic stressors in long-standing axial spondyloarthritis: association with patient and disease characteristics.
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.
Which definitions for MRI sacroiliac joint lesions predict the diagnosis of early axial spondyloarthritis best? A 2-year follow-up in the SPACE cohort.
Reducing selection bias while maintaining precision through an integrated analysis: 2-year longitudinal analysis of imaging outcomes in the SPondyloArthritis Caught Early cohort.
Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.
Development and validation analysis of a corrected axial spondyloarthritis metrology index (CASMI).
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis
The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis
<scp>EULAR</scp> /American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia
Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA study.
Evaluation of instruments assessing peripheral arthritis in spondyloarthritis: an analysis of the ASAS-PerSpA study.
Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA study.
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies.
Methodology of the development of the EULAR Antiphosholipid Syndrome Disease Activity Score (EAPSDAS)
Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis : A Retrospective Cohort Study.
Radiological phenotypes in pulmonary sarcoidosis: a reliability study of newly defined high-resolution computer tomography phenotypes.
ASAS recommendations on reporting axial spondyloarthritis clinical trials
ASAS recommendations on reporting axial spondyloarthritis clinical trials
Correspondence on 'Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoring' by Protopopov et al.
How calculating consensus change scores can go wrong: lessons from multireader imaging assessments in axial spondyloarthritis
Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
Sacroiliac damage on MRI in axial spondyloarthritis and chronic back pain, women with postpartum back pain, runners and healthy subjects.
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
ASAS consensus definition of early axial spondyloarthritis.
Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.